Overview

Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this real-world study is to evaluate the safety and efficacy of lipiodol-TACE with idarubicin for hepatocellular carcinoma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Zhongda Hospital
Treatments:
Idarubicin